Sort   by:  
 Page size 
ProteomicsProteomics for Roseburia intestinalis and Parabacteroides merdae exposed to isosteviol and duloxetine.
The objective of this project was to identify changes in protein expression in R. intestinalis and P. merdae as a response to the treatment with the antidepressant duloxetine, the sweetener isosteviol and a combination of both. 18 samples before and after treatment were collected for each of the two...
ORGANISM(S): Parabacteroides merdae Roseburia intestinalis 
2026-04-30 | PXD045140 | Pride
Proteomics Antidepressant duloxetine Gut bacteria Sweetener isosteviol 
MetabolomicsMetabolic cooperation and spatiotemporal niche partitioning in a kefir microbial community; Interaction between the kefir isolates Lactococcus lactis and Acetobacter fabarum (GC-MS)

Microbial communities often undergo intricate compositional changes yet also maintain stable coexistence of diverse species. The mechanisms underlying long-term coexistence remain unclear, as system-wide studies have been largely limited to engineered communities, ex situ adapted cultures, or syn...

2020-11-04 | MTBLS1830 | MetaboLights
MetabolomicsBioaccumulation of therapeutic drugs by human gut bacteria: duloxetine accumulation at different concentrations (L.saccharolytica;E.coli assays)

Bacteria in the gut can modulate the availability and efficacy of therapeutic drugs. Interactions at this level have only recently started to being systematically mapped and the main underlying mechanism proposed is chemical transformation of drugs by microbes (biotransformation). Here, we invest...

2021-07-20 | MTBLS1319 | MetaboLights
MetabolomicsBioaccumulation of therapeutic drugs by human gut bacteria (E.coli;C.saccharolyticum;S.salivarius;E.rectale;L.plantarum;L.lactis assays)

Bacteria in the gut can modulate the availability and efficacy of therapeutic drugs. Interactions at this level have only recently started to being systematically mapped and the main underlying mechanism proposed is chemical transformation of drugs by microbes (biotransformation). Here, we invest...

2021-07-20 | MTBLS1627 | MetaboLights
MetabolomicsBioaccumulation of therapeutic drugs by human gut bacteria: cross-feeding metabolite analysis (FIA-MS) (E.rectale;S.salivarius assays)

Bacteria in the gut can modulate the availability and efficacy of therapeutic drugs. Interactions at this level have only recently started to being systematically mapped and the main underlying mechanism proposed is chemical transformation of drugs by microbes (biotransformation). Here, we invest...

2021-07-20 | MTBLS1792 | MetaboLights
MetabolomicsBioaccumulation of therapeutic drugs by human gut bacteria: secreted metabolite analysis (FIA-MS) (C.saccharolyticum;E.coli;L.plantarum;L.lactis;S.salivarius assays)

Bacteria in the gut can modulate the availability and efficacy of therapeutic drugs. Interactions at this level have only recently started to being systematically mapped and the main underlying mechanism proposed is chemical transformation of drugs by microbes (biotransformation). Here, we invest...

2021-07-20 | MTBLS1791 | MetaboLights
MetabolomicsBioaccumulation of therapeutic drugs by human gut bacteria (B.animalis assays)

Bacteria in the gut can modulate the availability and efficacy of therapeutic drugs. Interactions at this level have only recently started to being systematically mapped and the main underlying mechanism proposed is chemical transformation of drugs by microbes (biotransformation). Here, we invest...

2021-07-20 | MTBLS1264 | MetaboLights
MetabolomicsBioaccumulation of therapeutic drugs by human gut bacteria (L.saccharolytica;Standards assays)

Bacteria in the gut can modulate the availability and efficacy of therapeutic drugs. Interactions at this level have only recently started to being systematically mapped and the main underlying mechanism proposed is chemical transformation of drugs by microbes (biotransformation). Here, we invest...

2021-07-20 | MTBLS2885 | MetaboLights
MetabolomicsBioaccumulation of therapeutic drugs by human gut bacteria: secreted metabolite analysis for resting cells (B.uniformis;C.saccharolyticum assays)

Bacteria in the gut can modulate the availability and efficacy of therapeutic drugs. Interactions at this level have only recently started to being systematically mapped and the main underlying mechanism proposed is chemical transformation of drugs by microbes (biotransformation). Here, we invest...

2021-07-20 | MTBLS1757 | MetaboLights
MetabolomicsImpact of low-calorie sweeteners on gut bacteria is modulated by commonly used xenobiotics

The gut microbiota is implicated in adverse effects associated with low-calorie sweeteners. Yet, the direct impact of sweeteners on gut bacteria has not been systematically assessed. Here we report interactions between 25 phylogenetically diverse gut bacterial strains and 39 commercially used swe...

2025-06-11 | MTBLS11480 | MetaboLights
Sort   by:  
 Page size